Review: Novel targets in the management of pneumonia

Marcos I. Restrepo, Luis A. Díaz, Eric M. Mortensen, Antonio Anzueto

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

Original languageEnglish (US)
Pages (from-to)387-400
Number of pages14
JournalTherapeutic Advances in Respiratory Disease
Issue number6
StatePublished - Dec 2008


  • community-acquired infections
  • intensive care unit
  • pneumonia
  • therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Review: Novel targets in the management of pneumonia'. Together they form a unique fingerprint.

Cite this